



Dec 02, 2023

TF and epigenetic modifier CRISPRi/a screens in human T cells

DOI

dx.doi.org/10.17504/protocols.io.bp2l6xy15lqe/v1

Sean R. McCutcheon¹, Adam M. Swartz¹, Michael C. Brown¹, Alejandro Barrera¹, Christian McRoberts Amador¹, Keith Siklenka¹, Lucas Humayun¹, Maria A. ter Weele¹, James M. Isaacs¹, Andrea R Daniel¹, Timothy E. Reddy¹, Andrew Allen¹, Smita K. Nair¹, Scott J. Antonia¹, Charles A. Gersbach¹

¹Duke University

Andrea R Daniel: This protocol was adapted from work of Sean McCutcheon and colleagues in the Gersbach lab at Duke University.

Gersbach Lab



Andrea R Daniel

Duke University

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.bp2l6xy15lqe/v1>

Protocol Citation: Sean R. McCutcheon, Adam M. Swartz, Michael C. Brown, Alejandro Barrera, Christian McRoberts Amador, Keith Siklenka, Lucas Humayun, Maria A. ter Weele, James M. Isaacs, Andrea R Daniel, Timothy E. Reddy, Andrew Allen, Smita K. Nair, Scott J. Antonia, Charles A. Gersbach 2023. TF and epigenetic modifier CRISPRi/a screens in human T cells.

protocols.io <https://dx.doi.org/10.17504/protocols.io.bp2l6xy15lqe/v1>

Manuscript citation:

McCutcheon, S.R., Swartz, A.M., Brown, M.C. *et al.* Transcriptional and epigenetic regulators of human CD8⁺ T cell function identified through orthogonal CRISPR screens. *Nat Genet* (2023). <https://doi.org/10.1038/s41588-023-01554-0>

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: December 02, 2023

Last Modified: December 02, 2023

Protocol Integer ID: 91700

Keywords: CRISPRi, CRISPRa, T cells, CCR7, methods for crispr interference, epigenetic modifier crispri, crispr interference, epigenetic regulators of human cd8, crispr, epigenetic regulator, human cd8, crispri, cell

Funders Acknowledgements:

NIH

Grant ID: HG012053

Abstract

This protocol describes methods for CRISPR interference or activation screens identifying transcriptional and epigenetic regulators of human CD8⁺ T cell state.

Materials

pLV hU6-gRNA hUbC-dSaCas9-KRAB-T2A-Thy1.1 (Addgene 194278)

pLV hU6-gRNA hUbC-VP64-dSaCas9-VP64-T2A-Thy1.1 (Addgene 194279)

Troubleshooting

TF and epi-modifier CRISPRi/a gRNA library construction

- 1 The TSSs for each TF and epi-modifier were extracted using CRISPick and 1,000-bp windows were constructed around each TSS (–500 to +500 bp).
- 2 After establishing an SaCas9 gRNA database with the strict PAM variant (NNGRRT) using guideScan⁶⁶, the genomic windows were input into the guidescan_guidequery function to generate the gRNA library.
- 3 Any gRNA that aligned to another genomic site with fewer than four mismatches was removed from the library. The final gRNA library contained at least seven gRNAs targeting 120/121 target gene (there were no *PBX2*-targeting gRNAs) with an average of 16 gRNAs per gene.
- 4 A total of 120 NT gRNAs were included in the library for a total of 2,099 gRNAs (available in Supplementary Table 2, McCutcheon et al. Nature Genetics, 2023. <https://doi.org/10.1038/s41588-023-01554-0>)

gRNA library cloning

- 5 Oligonucleotide pools containing variable gRNA sequences and constant regions for polymerase chain reaction (PCR) amplification were synthesized by Twist Bioscience.
- 6 gRNA amplicons were gel extracted, PCR purified and input into 20 µl Gibson reactions (5:1 molar ratio of insert to backbone) with 200 ng of Esp3I digested and 1 × solid-phase reversible immobilization (SPRI)-selected (Beckman Coulter) plasmid backbone.
- 6.1 Addgene: pLV hU6-gRNA hUbc-dSaCas9-KRAB-T2A-Thy1.1 (Addgene 194278) and pLV hU6-gRNA hUbc-VP64-dSaCas9-VP64-T2A-Thy1.1 (Addgene 194279).
- 7 Gibson reactions were purified using ethanol precipitation and transformed into Lucigen's Endura ElectroCompetent Cells.
- 8 Transformed cells were cultured overnight and plasmids were isolated using Qiagen Midi Kits.

Transfections for high-titer lentiviral production

- 9 Plate 1.2×10^6 or 7×10^6 HEK293T cells in a 6 well plate or 10 cm dish in the afternoon with 2 mL or 12 mL of complete opti-MEM (Opti-MEM[®] I Reduced Serum Medium supplemented with 1x Glutamax, 5% FBS, 1 mM Sodium Pyruvate, and 1x MEM Non-Essential Amino Acids).



- 10 The next morning, transfect HEK293T cells with 0.5 µg pMD2.G, 1.5 µg psPAX2, and 0.5 µg transgene for 6 well plates or 3.25 µg pMD2.G, 9.75 µg psPAX2, and 4.3 µg transgene for 10 cm dishes using Lipofectamine 3000.
- 11 Exchanged media 6 hours after transfection and collect and pool lentiviral supernatant at 24 hours and 48 hours after transfection.

Transduction of primary human T cells

- 12 Centrifuged lentiviral supernatant at 600g for 10 min to remove cellular debris.
- 13 Concentrate lentivirus to 50–100× the initial concentration using Lenti-X Concentrator (Takara Bio).
- 14 Transduce T cells at 5–10% v/v of concentrated lentivirus at 24 h post-activation. For dual transduction experiments, T cells were serially transduced at 24 h and 48 h.

TF and epi-modifier CRISPRi/a gRNA screens

- 15 CD8⁺CCR7⁺ T cells were sorted and transduced with either CRISPRi or CRISPRa TF + epi-modifier gRNA libraries at a low MOI.
- 16 Cells were expanded for 10 days and then stained for Thy1.1 (a marker to identify transduced cells) and CCR7 (a marker associated with T cell state).

16.1

Antibody Target	Fluorophore/Sequence	Clone	Isotype	Dilution	Application	Manufacturer	Catalog #	Notes
CCR7	FITC	150503	Mouse IgG2a	1:100	Flow cytometry	BD Biosciences	561271	Stain at 37C
Thy1.1	PE	OX-7	Mouse IgG1, κ	1:300	Flow cytometry	StemCell Technologies	60024 PE	-

- 17 An SH800 FACS Cell Sorter (Sony Biotechnology) was used for cell sorting and analysis.

- 18 For antibody staining of Thy1.1 cells were collected, spun down at 300*g* for 5 min, resuspended in flow buffer (1× phosphate-buffered saline (PBS), 2 mM ethylenediaminetetraacetic acid and 0.5% bovine serum albumin) with the appropriate antibody dilutions and incubated for 30 min at 4 °C on a rocker. Antibody staining of CCR7 was carried out for 30 min at 37 °C.
- 19 Cells were then washed with flow buffer, spun down at 300*g* for 5 min and resuspended in flow buffer for cell sorting.
- 20 Transduced cells in the lower and upper 10% tails of CCR7 expression were sorted for subsequent gRNA library construction and sequencing. All replicates were maintained and sorted at a minimum of 300× coverage.

gRNA sequencing

- 21 Genomic DNA was isolated using Qiagen's DNeasy Blood and Tissue Kit. Genomic DNA was split across 100 µl PCR reactions (25 cycles at 98 °C for 10 s, 60 °C for 30 s, and 72 °C for 20 s) with Q5 2× Master Mix and up to 1 µg of genomic DNA per reaction.
- 22 PCRs were pooled together for each sample and purified using double-sided (SPRI) bead selection at 0.6× and 1.8×.
- 23 Libraries were run on a High Sensitivity D1000 tape (Agilent) to confirm amplicon size and quantified using Qubit's dsDNA High Sensitivity assay.
- 24 Libraries were diluted to 2 nM, pooled together at equal volumes, and sequenced using Illumina's MiSeq Reagent Kit v2 (50 cycles).
- 25 Primers are available in Supplementary Table 5 of McCutcheon et al. Nature Genetics, 2023. <https://doi.org/10.1038/s41588-023-01554-0>

Processing gRNA sequencing and gRNA analysis

- 26 FASTQ files were aligned to custom indexes for each gRNA library (generated from the bowtie2-build function) using Bowtie 2 (ref. [67](#)).
- 27 Counts for each gRNA were extracted and used for further analysis in R.

- 28 Individual gRNA enrichment was determined using the DESeq2 (ref. **68**) package to compare gRNA abundance between groups for each screen.

Gene-level analysis for CRISPRi/a screens

- 29 DESeq2 P values were empirically transformed to cumulative probabilities using a midpoint linear interpolation of the 120 NT gRNA P values between 0 and 1. This transformation aligns the data with the null hypothesis that NT gRNA P values have a uniform distribution between 0 and 1.
- 30 Within each gene, transformed P values were aggregated using a modified robust rank aggregation method to detect genes with nonuniform (non-null) gRNA P values.
- 31 A gene-level P value was produced by comparison with 10 million gene-level null simulations of P values randomly sampled from a uniform distribution.
- 32 NT gRNAs were randomly grouped into NT control 'genes' (NTCs) and analyzed in the same way.
- 33 The number of gRNAs per NTC was sampled with replacement from the distribution of gRNAs per gene in the screen until all the NT gRNAs were used.
- 34 Genes were selected as hits if their Benjamini–Hochberg false discovery rate (FDR) was less than 0.05. Gene-level aggregation was done in Python.
- 35 Two effect sizes were computed for each gene by averaging gRNAs' unshrunk DESeq2 \log_2 FoldChange within the gene, weighted by each gRNA's transformed one-sided P value.
- 36 The larger (absolute value) effect size was chosen for each gene. Effect sizes were estimated in R.

Protocol references

67. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359 (2012).
68. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).